Table 7.
Agents used in the treatment of patients with COVID-19 and Influenza co-infection among a total of 29 evaluated patients.
| Agent | Number of studies | n* (%) | ||
|---|---|---|---|---|
| Antiviral drug | Peramivir | 1 | 1 (3.4) | |
| Cefaclor | 1 | 1 (3.4) | ||
| Oseltamivir | 8 | 12 (41.4) | ||
| Lopinavir–ritonavir | 1 | 4 (13.8) | ||
| Lianhua qingwen | 1 | 1 (3.4) | ||
| Antibacterial drug | Azithromycin | 4 | 7 (24.1) | |
| Ceftriaxon | 3 | 5 (17.2) | ||
| Levofloxacin | 2 | 3 (10.3) | ||
| Other | Hydroxychloroquine | 4 | 9 (31.0) | |
| Combination therapy | Oseltamivir, Levofloxacin | 1 | 1 (3.4) | |
| Oseltamivir, Cefaclor | 1 | 1 (3.4) | ||
| Oseltamivir, Lianhua qingwen | 1 | 1 (3.4) | ||
| Oseltamivir, Ceftriaxon, Azithromycin | 1 | 1 (3.4) | ||
| Oseltamivir, Hydroxychloroquine, Ceftriaxon, Azithromycin | 2 | 3 (10.3) | ||
| Hydroxychloroquine, Lopinavir–ritonavir | 1 | 4 (13.8) |
*
n, number of co-infected patients' receiving each medication.